ImmunotherapyPhase 3 trialInvestigational
Durvalumab + tremelimumab
How it works
Combination of two immunotherapy agents: durvalumab and tremelimumab. Durvalumab blocks the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells, while tremelimumab blocks the CTLA-4 receptor, further enhancing immune response.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Durvalumab plus tremelimumab has shown promise in improving overall survival in patients with metastatic pancreatic cancer, but its effectiveness is still being studied.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.